HISTOINDEX PTE. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HistoIndex Charts New Course in Liver Disease Innovation: Announces Pivotal Changes to Scientific Advisory Board 2024-07-01 20:00
TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH 2023-06-15 20:00
HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors 2022-05-18 19:00
HistoIndex and Global Liver Experts Advance Stain-free AI Quantification of Hepatocyte Ballooning as a Reproducible Approach and Potential Endpoint for NASH Clinical Trials 2022-04-27 17:34
HistoIndex Explores the Clinical Utility of Stain-free AI Digital Pathology Platform in 388 Patients with Triple-Negative Breast Cancer (TNBC) 2021-01-25 06:00
HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China 2020-05-25 06:00
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features 2019-11-11 13:28
HistoIndex's Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal's Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial 2018-12-24 08:28
HistoIndex's Second Harmonic Generation (SHG) Technology: A Potentially Important Tool Used In Madrigal's Phase 2 Nonalcoholic Steatohepatitis (NASH) Clinical Trial 2018-12-23 17:00
1